Evidence map›Paper›PMID 30972712›Full record

ArticleJournal of thrombosis and thrombolysis2019

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin.

Patricia O Guimarães, Renato D Lopes, John H Alexander, Laine Thomas, Anne S Hellkamp, Ziad Hijazi, Elaine M Hylek, Bernard J Gersh, David A Garcia, Freek W A Verheugt and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease.European heart journal supplements : journal of the European Society of Cardiology · 2022
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Patricia O GuimarãesDuke Clinical Research Institute, Durham, NC, 27705, USA.
Renato D LopesDuke Clinical Research Institute, Durham, NC, 27705, USA. renato.lopes@dm.duke.edu.ORCID http://orcid.org/0000-0003-2999-4961
John H AlexanderDuke Clinical Research Institute, Durham, NC, 27705, USA.
Laine ThomasDuke Clinical Research Institute, Durham, NC, 27705, USA.
Anne S HellkampDuke Clinical Research Institute, Durham, NC, 27705, USA.
Ziad HijaziUppsala Clinical Research Center, Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
Elaine M HylekBoston University Medical Center, Boston, MA, USA.
Bernard J GershDepartment of Cardiovascular Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA.
David A GarciaDivision of Hematology, Department of Medicine, University of Washington, Medical Center, University of Washington School of Medicine, Seattle, WA, USA.
Freek W A VerheugtAfdeling Cardiologie, Hartcentrum OLVG, Amsterdam, The Netherlands.
Michael HannaBristol-Myers Squibb, Princeton, NJ, USA.
Greg FlakerUniversity of Missouri School of Medicine, Columbia, MO, USA.
Dragos VinereanuUniversity of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Christopher B GrangerDuke Clinical Research Institute, Durham, NC, 27705, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We explored associations between INR measures and clinical outcomes in patients with AF using warfarin, and whether INR history predicted future INR measurements. We included patients in ARISTOTLE who were randomized to and received warfarin. Among patients who had events, we included those with ≥ 3 INR values in the 180 days prior to the event, with the most recent ≤ 60 days prior to the event, who were on warfarin at the time of event (n = 545). Non-event patients were included in the control group if they had ≥ 180 days of warfarin exposure with ≥ 3 INR measurements (n = 7259). The median (25th, 75th) number of INR values per patient was 29 (21, 38) over a median follow-up of 1.8 years. A total of 87% had at least one INR value < 1.5; 49% had at least one value > 4.0. The last INRs before events (median 14 [24, 7] days) were < 3.0 for at least 75% of patients with major bleeding and > 2.0 for half of patients with ischemic stroke. Historic time in therapeutic range (TTR) was weakly associated with future TTR (R

Indexed as

AgedAtrial FibrillationBrain IschemiaCase-Control StudiesFemaleHemorrhageHumansInternational Normalized RatioMaleMiddle AgedPredictive Value of TestsStrokeTreatment OutcomeWarfarinWarfarinAtrial fibrillationClinical outcomesInternational normalized ratioWarfarin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.